Yes, Promacta is growing faster than Nplate and at this rate may catch them by Q4 (assuming no unilateral price increases).
Promacta just reported 2Q at 31% growth over prior yr qtr, with a 17% Q2/Q1 in the US.
Nplate? 2Q at 23% growth over prior qtr, with an ugly 0% Q2/Q1 growth in the US.
As nucs provide potential for all oral Tx, injectable Nplate is even more disfavored for HVC vs oral Promacta. So even with 0% growth, the combination of Nplate & Promacta results provide further support for those that believe anti-thrombo Rx will still have a place. Even with nucs in HCV.
I like Irina's work. And as a fellow NYU MBA grad, I've wanted to like her work on Ligand too. Sadly, her work here has been very inconsistent, and boarders on spiteful after Cantor Fitzgerald was passed over to run $LGND's old ATM facility.
A) Promacta: her quarterly sales forecasts have been consistently lagged consensus and what $GSK has actually produced.
B) Debt: When Ligand snubbed CF, she started saying she had a concern $LGND was using debt to do M&A. Who knows where she got this. The company has mostly used combination of equity and CVRs to get deals done; not debt. In fact $LGND will be debt free by the end of the month. But to be clear, I actually FAVOR $LGND's use reasonable debt at low costs vs dilutive equity offerings to acquire accretive revenue streams.
C) Captisol: She was concerned the 4Q13 Captisol sales jump was just front loading, rather than a true increase in sales. Q1 & Q2 results show her fears there were unfounded.
D) She has stated, "owning LGND which depends on royalty streams from a diverse product basket (some highly valuable, others less so), is not the same as owning shares in a biotech company with a unique and differentiated asset..." AND I AGREE. But she fails to understand the value of this portfolio effect. A diverse basket of royalty streams should have MUCH LESS RISK (and thus be MORE valuable) often recognized by applying a lower WACC discount. But Irina's work uses the SAME WACC for Ligand as she uses for all other biotechs. That makes zero sense. A pre earnings biotech with a key lead asset has HUGE risks; both technical success risks and financing risks.
E) BACE1: Previously she had stated that she had yet to include it in valuation given she had low expectations it would meet Ph2. But claimed that if it did go into Ph3, it would have a major impact. Yet when the data proved she was wrong and $MRK did go into Ph3, she merely added $1/sh w/o running the numbers. Weak effort.
$52 is the technical level that will start the squeeze. Bought some around $51 today as well as some Aug 50 calls. Lemelson may be "silly", but I doubt he's stupid. This was a well orchestrated bear raid, so expect him to take his profits while he can and move on...and if he's really smart, he'll flip to a long (just as he did on his WWE short raid a few months back.)
Sentiment: Strong Buy
Super sweet. But no, "Novartis reps" are not yet selling epog. Of course, the GSK reps who sell epog will soon become Novartis reps... and suddenly have extreme motivation to turn it up a notch or risk losing their jobs with the inevitable sales force realignments & RIF.
Woody is right. But Lemelson also has created an opportunity for all us longs..to buy more. And I expect this might one reason $LGND issued their earnings report a bit early... we didn't expect them till later in the month. But by moving up the date, it frees the board and management to buy more shares them self. As such, I fully expect to see a few new filing for purchases in the coming weeks. Especially before they employ the buyback.
BTW, note that Lemelson was once a vocal short in WWE, but is now a long. So I suspect that they might soon be taking their profits on $LGND as well - and perhaps eventually "flipping the switch" to a long, given they will not wish to risk their gains with upcoming catalysts including GSK Promacta earnings & new indication approvals. I don't believe the Priest truly believes Ligand is insolvent or on a path to a $0 PT.
Sentiment: Strong Buy
Fair points, but still great to see the beat. Yet giving any update on guidance will be a challenge and guess for LGND at this tick. By Aug 4th, GSK should have reported their Q2 Promacta results (which will drive $LGND Q3 results) and we might also get some update on the sale to Novartis.
Sentiment: Strong Buy
Our work suggests the current price flush was primed by fear over Promacta sales for 2Q14 along with Lemelson's zany short case thesis which helped develop a technical bearish pattern, that was then triggered by Fed Yellin's comments about over priced biotech stocks. As of last rpt (6/30) $LGND already had an extremely high short interest over 17% of the float, and we expect the SI for the 7/15 rpt will be over 20%. Bottom line? Getting primed for a massive short squeeze on Aspire / Focus trial data readout this qtr.
Sentiment: Strong Buy
BTW, these rain fall tally are much worse than then the drought impact was predicted in April, when the San Diego Union Tribune ran a story predicting the price of Avocados to rise by 28% and lettuce by 34% see ("Drought sends produce prices climbing" April 21, 2014)
Today marks the end of the "rain year" the standard period for measurement for precipitation (why it is not a calandar yr? who knows!).
Here in San Diego, local news KPBS is reporting the third driest period for the county on record. Just 5.06 inches vs ave 10.34. (Google it)
This is very bad news for the county's largest single species cash crop...the avocado. San Diego county is largest domestic producer of avocado, with about 60% of the US crop. And avocado is known as a rather thirsty tree, so with the rising costs of irrigation water, the number of trees in production will continue its long decline.
All this supports the view that domestic supply will continue to fall, just as demand for the fruit has grown. As such, price will continue to climb. And given Chipotle is one of the largest buyers of US avocado's, and does not hedge? Further source of future margin pressure.
Just another straw of bad new as $CMG traces out what looks like a massive technical double top, yet is at or near historic lows for its short interest. At a minimum, expecting a significant pull back as it starts a flag pattern.
So CNBC's Cramer, who arguibly helped annoint $CMG, is "buying a sweater" and urging viewers that $MCD (with it's global foot print, value range P/E and higher than the 10yr dividend) is a better holding in these markets.
Long time viewers know that Cramer is a life long member of the "church of what's working now". And he's leaving $CMG primarily for one reason. The CMG chart is cracked badily and in big danger of being totally broken.
Since 4/17 with its UGLY techncial outside reversal, $CMG tested and broke its MA(200)d, and set a lower swing low. Since then it has been just riding this average as it too is flattening (dealth for a momo stock). In fact since it's March 21 high, $CMG has painted a classic bear flag on the daily chart. As such, if it closes below its MA(200)d again, and then closes lower than THAT close in one of the two sessions to follow, the probability of a future close below $484.5 will be virtually assured, setting up a test of the swing low and possible new LSL.
So what .. a little swoon? What is Cramer afraid of? He fears that if that breaks, there is no technical support till mid to low $400's. A buyer strike with all eyes will be on the gap fill to $447.65, the 2012 $442.4 high, and the 50% FIB retrace at $427.84.
And if the value cycle lasts? It would need to fall much MUCH more.
Yep... And the next gen BEATS streaming service was to be built into the headset.
Still, if companies like APPL and Sam are smart, they will seek to expand and defend horizontally into the high margin accessory biz. Keyboard w/ tablets are a no brainer. And as was the case with BEATS, it may be quicker and easier to buy tech & market share than to build from scratch.
So what is behind your "trading day" deadline? 1Q14 cc? I see the real deadline as PM of May 12th, when the ASCO abstracts are made public.
I'm in stalking / DD mode on GSVC, so would be pleased to have real conversations here on GSVC. As I've written elsewhere, technicals and my theory that GSVC has been a hedge vehicle for locked up TWTR (and before that FB) longs has kept me on the sidelines. But if/when a squeeze cycle starts, this name should outperform. Still, in the near term my guess is that the $8.46 level it hit today (78.6% Fib extension) is likely to be retested. (no pos).
You do know, Dennis, that you are replying to a SPAMbot, yes? Firstname.lastnamethreedigit for USERID is the tell.
But I've a q for you. I've been following GSVC for years, and in general love their concept, though the BDC model does have some drawbacks. But I've not purchased in part as I've feared they have been a way for lockedup TWTR longs to hedge (short). Now that the big TWTR lock up is over and taking the expected bath, I see GSVC is down less than it should be, which suggests to me as long TWTR is getting sold, the pair trade (short GSVC is also starting to be unwound.) Technically, GSVC is still a mess and a no touch from that point of view, but is becoming a deep value play which has me in stalking mode. Do you (or any others) see any holes in this view?
Hexagon in far from a "new" player in the cng tank biz. The stock is reacting to agility adding hexagon tanks to its offering and possibly signalling a vendor switch. But the impact for qtwe is as yet unknown. I expect qtww will still have some sales through agility. Also qtww is developing other system integrators as clients (ZHEO) and even have technology that should permit them to move "downstream" to be a direct OEM rather then just a tank vendor. Still, if the stock stays depressed, I wouldn't be surprised to see 3M or Lucifer make a run at them soon.